New Insights in Alzheimer’s Research

There might be a promising development in the fight against Alzheimer’s disease. Recent research has suggested a strong connection between lithium levels in the brain and Alzheimer’s, indicating that lithium supplements might be able to reverse memory loss similar to that seen in Alzheimer’s in mice.

This study, spearheaded by a team from Harvard Medical School, aimed to explore the links previously established between exposure to certain metals and the risk of dementia.

Researchers examined numerous donated brain tissues and blood samples from individuals with advanced Alzheimer’s, those showing early signs of mild cognitive impairment (MCI), and individuals with no cognitive issues. The team conducted tests focusing on various metals.

Interestingly, only lithium demonstrated significant differences in levels among the groups. Reduced lithium levels were particularly evident even in the early stages of memory decline among the samples.

“The notion that lithium deficiency might contribute to Alzheimer’s is a novel one, suggesting a fresh direction for treatment,” says Bruce Yankner, a geneticist and neurologist at Harvard Medical School.

Although lithium is commonly used for treating bipolar disorder, this marks the first instance where its natural presence in the brain has been noted.

“It turns out lithium is similar to other essential nutrients we acquire from our environment, like iron and vitamin C,” Yankner continues. “This is the first time anyone has shown lithium exists at a natural level that has biological significance without being administered as medication.”

Further examinations revealed that amyloid-beta protein clumps—the classic marker of Alzheimer’s—seemed to latch onto lithium in the brain, reducing its availability to neurons and hastening the disease’s advancement.

In their experiments on mice, researchers noted that a lack of lithium drastically increased amyloid-beta clumps in their brains, along with higher levels of another Alzheimer’s-related protein known as tau.

On a positive note, the study found that a specific form of lithium, called lithium orotate, could avoid capture by amyloid-beta proteins. Administering small doses of this lithium type to mice exhibiting Alzheimer’s-like symptoms notably restored their memory functions, effectively reversing some cognitive decline.

However, many questions remain, which is typical in Alzheimer’s research, as this is a particularly intricate disease. For instance, it’s still unclear what causes lithium levels to decrease and how that correlates with dementia symptoms.

Further investigations are necessary to shed light on these issues. Clinical trials are the next critical phase. Eventually, testing lithium levels in patients might provide a way to diagnose Alzheimer’s earlier, while lithium supplements could serve as a preventative or therapeutic option.

With the increasing number of people affected by dementia, there’s a pressing need to discover methods to safeguard the brain from the severe impacts of this condition.

“It’s important to be cautious in drawing conclusions from mouse studies, since we won’t know for sure until we conduct controlled human clinical trials, but the current findings are quite promising,” Yankner notes.

The study findings have been published in Nature.